Compare Novartis AG (NVS) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Royal Bank of Canada — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Royal Bank of Canada trades at $210.37 (market cap $289.51B). The key difference: Novartis AG and Royal Bank of Canada are close in size by market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | RY | |
|---|---|---|
Market Cap | $290.25B | $289.51B |
Sector | Health | Financials |
52-Week High | $168.62 | $217.87 |
52-Week Low | $113.50 | $128.46 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
